# Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis

> **NCT00748410** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 3 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** SB-656933

## Key facts

- **NCT ID:** NCT00748410
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01-22
- **Primary completion:** 2009-12-12
- **Final completion:** 2009-12-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** SB-656933 is no longer being developed for ulcerative colitis.
- **Last updated:** 2020-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748410, "Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00748410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*